Characterization of Leukemic Resistance to CD19-Targeted CAR T-cell Therapy through Deep Genomic Sequencing

Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has been a clinical breakthrough for pediatric B-cell acute lymphoblastic leukemia (B-ALL), and loss of the CD19 target antigen on leukemic cells represents a major mechanism of relapse. Previous studies have observed CD19 mutations speci...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Gregory M., Chen, Chia-Hui, Perazzelli, Jessica, Grupp, Stephan A., Barrett, David M., Tan, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Priority Briefs
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808313/
https://www.ncbi.nlm.nih.gov/pubmed/36255409
http://dx.doi.org/10.1158/2326-6066.CIR-22-0095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808313/
https://www.ncbi.nlm.nih.gov/pubmed/36255409
http://dx.doi.org/10.1158/2326-6066.CIR-22-0095

Ejemplares similares